Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 52Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 36Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Neoplasms 29Biliary Tract Neoplasms 29Neoplasm Metastasis 28Cholangiocarcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Ovarian Neoplasms 24Head and Neck Neoplasms 19Liver Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 15Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

pembrolizumab 2toripalimab 1sintilimab 1pemigatinib 1osimertinib 1durvalumab 1Vinorelbine 1Platinum Compounds 1Nivolumab 1Ipilimumab 1Drug Therapy 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non Small Cell Lung Cancer × durvalumab × Clear all
NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

AstraZeneca

Phase 1 Active not recruiting
344 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡